Humana Upgrade: Buy the Dip — Medicare Tailwinds and a Reasonable Entry Point
Humana (HUM) slid after weak fiscal-2026 EPS guidance and membership softness, but the CMS 2027 Medicare Advantage capitation boost, solid cash flow, and an attractive enterprise multiple argue for a tactical buy on weakness. I upgrade to Buy with a clear entry, stop, and target for a swing/position trade over the next 45 trading days.